Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers in this study want to find the best dose of STAR0602 to use in people with advanced solid tumors. The people in this study have cancer that is inoperable (cannot be taken out with surgery) or metastatic (has spread). STAR0602 boosts the immune system to stop tumor growth. It is given intravenously (by vein).
Researchers are doing this study to see if Revaree Plus improves vaginal health in people treated for breast cancer. The people in this study are having symptoms of vaginal dryness or discomfort during breast cancer treatment.
Researchers want to see if AAA617 can slow the growth of advanced prostate cancer. They also want to learn if this treatment can delay the need to start hormonal therapy. Treatment with AAA617 will be compared to observation (no treatment other than standard targeted radiation therapy).
Researchers want to see if zongertinib is safe and works well to treat advanced solid tumors. The people in this study have solid tumors that metastasized (spread). The tumors contain an abnormal HER2 protein (mutation) or too much HER2 (overexpression/amplification). HER2 promotes the growth of cancer cells.
Roginolisib works by blocking a protein called PI3K-delta. By blocking this protein, roginolisib may strengthen your immune system's ability to fight cancer cells. It is taken orally (by mouth).
The purpose of this study is to see if the drug pasireotide works well to treat prolactinomas. Prolactinomas are noncancerous pituitary gland tumors that make too much prolactin. Prolactin is a hormone that causes the body to make less estrogen and testosterone (sex hormones).
The purpose of this study is to see how well sotorasib works in people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS G12C gene. This mutation can cause cancer cells to grow. In addition, the people in this study have not received treatment for their cancer since it became advanced.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In people born with certain genetic mutations or whose tumors have these mutations, the standard treatment for breast cancer with CDK4/6 inhibitors (like palbociclib, ribociclib, or abemaciclib) might not be as effective. However, their tumors may still respond to a different type of drug called PARP inhibitors.
